Clinical qualification; drug development tool; personalized healthcare/medicine
Abstract :
[en] CONTEXT: Specific soluble biomarkers could be a precious tool for diagnosis, prognosis and personalized management of osteoarthritic (OA) patients. OBJECTIVE: To describe the path of soluble biomarker development from discovery to clinical qualification and regulatory adoption toward OA-related biomarker qualification. METHODS AND RESULTS: This review summarizes current guidance on the use of biomarkers in OA in clinical trials and their utility at five stages, including preclinical development and phase 1 to phase 4 trials. It also presents all the available regulatory requirements. CONCLUSIONS: The path through the adoption of a specific soluble biomarker for OA is steep but is worth the challenge due to the benefit that it can provide.
Research Center/Unit :
d‐BRU - Dental Biomaterials Research Unit - ULiège
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Sanchez, Christelle ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Cornet, Anne
Van de Put, Joachim
Douette, Pierre
Gharbi, Myriam
Language :
English
Title :
Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine.
Publication date :
2015
Journal title :
Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
Armbruster DA, Pry T. (2008). Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev 29: S49-52
Bauer DC, Hunter DJ, Abramson SB, et al. (2006). Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14: 723-7
Baumgartner C, Osl M, Netzer M, Baumgartner D. (2011). Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinform 1: 2. doi: 10.1186/2043-9113-1-2
Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95
Birmingham JD, Vilim V, Kraus VB. (2007). Collagen biomarkers for arthritis applications. Biomark Insights 1: 61-76
Deberg M, Dubuc JE, Labasse A, et al. (2008). One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 67: 168-74
Deberg M, Labasse A, Christgau S, et al. (2005). New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13: 258-65
FDA, USDOHAHS, CDER, CVM. (2013). Guidance for industry: bioanalytical method validation. Revision 1 ed. Silver Spring (MD): Food and Drug Administration
Fleming TR, Powers JH. (2012). Biomarkers and surrogate endpoints in clinical trials. Stat Med 31: 2973-84
Gharbi M, Deberg M, Henrotin Y. (2011). Application for proteomic techniques in studying osteoarthritis: a review. Front Physiol 2: 90. doi: 10.3389/fphys.2011.00090
Henrotin Y, Addison S, Kraus V, Deberg M. (2007). Type II collagen markers in osteoarthritis: what do they indicate? Curr Opin Rheumatol 19: 444-50
Henrotin Y, Gharbi M, Mazzucchelli G, et al. (2012). Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 64: 2260-7
Hsueh MF, Onnerfjord P, Kraus VB. (2014). Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol 39: 56-66
Karsdal MA, Christiansen C, Ladel C, et al. (2014). Osteoarthritis-a case for personalized health care? Osteoarthritis Cartilage 22: 7-16
Kraus VB. (2012). Patient evaluation and OA study design: OARSI/biomarker qualification. HSS J 8: 64-5
Kraus VB, Blanco FJ, Englund M, et al. (2015). OARSI Clinical Trials Recommendations: soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 23: 686-97
Kraus VB, Burnett B, Coindreau J, et al. (2011). Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 19: 515-42
Lohmander LS, Dahlberg L, Ryd L, Heinegard D. (1989). Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 32: 1434-42
Lohmander LS, Saxne T, Heinegard DK. (1994). Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 53: 8-13
Lotz M, Martel-Pelletier J, Christiansen C, et al. (2013). Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis 72: 1756-63
Mahjoub M, Berenbaum F, Houard X. (2012). Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int 23: S841-6
Man GS, Mologhianu G. (2014). Osteoarthritis pathogenesis-a complex process that involves the entire joint. J Med Life 7: 37-41
Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. (2004). The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 294: 145-53
Schalken JA. (2010). Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 58: 19-20
van Spil WE, Degroot J, Lems WF, et al. (2010). Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthr Cartil 18: 605-12
Wagner JA, Williams SA, Webster CJ. (2007). Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81: 104-7
